Endocrinopathies with use of cancer immunotherapies.
Endocrinopathies with use of cancer immunotherapies.
复制标题
使用癌症免疫疗法治疗内分泌疾病。
DOI：
10.1111/cen.13483
复制
发表时间：
2018-03
影响因子：
3.2
通讯作者：
Leung AM
中科院分区：
文献类型：
--
作者：
Villa NM;Farahmand A;Du L;Yeh MW;Smooke-Praw S;Ribas A;Chmielowski B;Cherry G;Leung AM
免疫调节疗法，包括CTLA-4和PD-1抑制剂，通过防止T细胞失活来提供针对癌细胞的定向攻击。然而，这些药物也会阻止自身反应性T细胞的下调，导致免疫相关不良事件（IRAE）。报告显示内分泌IRAE的发生率不同，范围为0- 63%。描述接受癌症免疫调节治疗的患者中内分泌IRAE的频率和临床特征。回顾性队列研究。2009年至2016年期间在我们机构接受伊匹单抗、纳武单抗和/或派姆单抗处方的388例年龄≥18岁的患者。使用生化标准定义免疫调节治疗后的内分泌IRAE，包括甲状腺、垂体、胰腺和肾上腺功能障碍。在我们的队列中发生了50例内分泌IRAE，相应的发生率为12.9%。最常见的内分泌IRAE为甲状腺功能障碍（11.1%），垂体功能障碍的发生率较低（1.8%的患者）。在我们的研究样本中，超过12%接受伊匹单抗、纳武单抗和/或派姆单抗的患者发生了内分泌IRAE。应监测接受免疫调节治疗的患者是否发生内分泌IRAE。
Immunomodulatory therapies, including CTLA-4 and PD-1 inhibitors, provide a directed attack against cancer cells by preventing T cell deactivation. However, these drugs also prevent the down-regulation of auto-reactive T cells, resulting in immune-related adverse events (IRAEs). Reports show a varied incidence of endocrine IRAEs, ranging from 0–63%. To describe the frequency and clinical characteristics of endocrine IRAEs in patients taking cancer immunomodulatory therapies. Retrospective cohort study. 388 patients aged ≥18 years who were prescribed ipilimumab, nivolumab, and/or pembrolizumab between 2009–2016 at our institution. Biochemical criteria were used to define endocrine IRAEs, including thyroid, pituitary, pancreas, and adrenal dysfunction, following use of immunomodulatory therapies. 50 endocrine IRAEs occurred in our cohort, corresponding to a rate of 12.9%. The most common endocrine IRAEs were thyroid dysfunction (11.1%), with a lower incidence of pituitary dysfunction (1.8% of patients). Over 12% of patients receiving ipilimumab, nivolumab, and/or pembrolizumab in our study sample developed an endocrine IRAE. Patients who undergo treatment with immunomodulatory therapies should be monitored for the development of endocrine IRAEs.
登录
查看更多内容
影响因子：
51.1
作者：
Ribas, Antoni;Puzanov, Igor;Dummer, Reinhard;Schadendorf, Dirk;Hamid, Omid;Robert, Caroline;Hodi, F. Stephen;Schachter, Jacob;Pavlick, Anna C.;Lewis, Karl D.;Cranmer, Lee D.;Blank, Christian U.;O'Day, Steven J.;Ascierto, Paolo A.;Salama, April K. S.;Margolin, Kim A.;Loquai, Carmen;Eigentler, Thomas K.;Gangadhar, Tara C.;Carlino, Matteo S.;Agarwala, Sanjiv S.;Moschos, Stergios J.;Sosman, Jeffrey A.;Goldinger, Simone M.;Shapira-Frommer, Ronnie;Gonzalez, Rene;Kirkwood, John M.;Wolchok, Jedd D.;Eggermont, Alexander;Li, Xiaoyun Nicole;Zhou, Wei;Zernhelt, Adriane M.;Lis, Joy;Ebbinghaus, Scot;Kang, S. Peter;Daud, Adil
通讯作者：
Daud, Adil
影响因子：
158.5
作者：
Robert, Caroline;Schachter, Jacob;Ribas, Antoni
通讯作者：
Ribas, Antoni
DOI：
10.1210/jc.2016-2300
发表时间：
2016-11
期刊：
The Journal of clinical endocrinology and metabolism
影响因子：
--
作者：
de Filette J;Jansen Y;Schreuer M;Everaert H;Velkeniers B;Neyns B;Bravenboer B
通讯作者：
Bravenboer B
影响因子：
120.7
作者：
Ribas, Antoni;Hamid, Omid;Robert, Caroline
通讯作者：
Robert, Caroline
DOI：
10.1056/nejmoa1507643
发表时间：
2015-10-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Borghaei H;Paz-Ares L;Horn L;Spigel DR;Steins M;Ready NE;Chow LQ;Vokes EE;Felip E;Holgado E;Barlesi F;Kohlhäufl M;Arrieta O;Burgio MA;Fayette J;Lena H;Poddubskaya E;Gerber DE;Gettinger SN;Rudin CM;Rizvi N;Crinò L;Blumenschein GR Jr;Antonia SJ;Dorange C;Harbison CT;Graf Finckenstein F;Brahmer JR
通讯作者：
Brahmer JR